MARKER FOR PROGNOSIS OF A CLINICAL OUTCOME OF AN AUTOLOGOUS INTERVERTEBRAL DISC CELL TRANSPLANTATION, FOR PROGRESS ASSESSMENT/PROGRESS MONITORING OF AN AUTOLOGOUS INTERVERTEBRAL DISC CELL TRANSPLANTATION, FOR ASSESSING THE QUALITY OF INTERVERTEBRAL DISC CELLS, FOR ASSESSING THE QUALITY OF AN IMPLANT AND/OR MEDICATION FOR NOVEL THERAPIES (ATMP) FOR THE TREATMENT OF AN INTERVERTEBRAL DISC DEFECT, AND FOR DIAGNOSIS OF AN INTERVERTEBRAL AND/OR SPINAL COLUMN DEFECT

摘要

The invention relates to markers for use in vitro in the prediction (prognosis) of a clinical outcome (so-called outcome prognosis) of an autologous intervertebral disc cell transplantation, in particular a matrix-associated autologous intervertebral disc cell transplantation, and/or progress assessment/progress monitoring of an autologous intervertebral disc cell transplantation, in particular a matrix-associated autologous intervertebral disc cell transplantation, and/or in the assessment of the quality of intervertebral disc cells, preferably for an autologous intervertebral disc cell transplantation, in particular for a matrix-associated autologous intervertebral disc cell transplantation, and/or in the assessment of quality of an implant and/or a medication for novel therapies (ATMP) for the treatment of an intervertebral disc defect and/or for the reconstruction of intervertebral disc tissue and/or in the diagnosis of an intervertebral disc defect, in particular a lumbar, preferably lumbar-sacral intervertebral disc defect, and/or spinal column defect, wherein the marker is selected from the group consisting of CTX-I, CTX-II, NTX-I, CPII, VEGF, C2C, MMP-3, hyaluronic acid, TNF-α, IL-1ra, IL-4, COMP, YKL-40 and combinations of at least two of said markers. The invention further relates to a corresponding in vitro method and to a corresponding kit.